CL2024001831A1 - Uso del interferón como adyuvante en vacunas - Google Patents
Uso del interferón como adyuvante en vacunasInfo
- Publication number
- CL2024001831A1 CL2024001831A1 CL2024001831A CL2024001831A CL2024001831A1 CL 2024001831 A1 CL2024001831 A1 CL 2024001831A1 CL 2024001831 A CL2024001831 A CL 2024001831A CL 2024001831 A CL2024001831 A CL 2024001831A CL 2024001831 A1 CL2024001831 A1 CL 2024001831A1
- Authority
- CL
- Chile
- Prior art keywords
- vaccines
- interferon
- adjuvant
- fish
- disclosed
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 102000014150 Interferons Human genes 0.000 title abstract 3
- 108010050904 Interferons Proteins 0.000 title abstract 3
- 229940079322 interferon Drugs 0.000 title abstract 3
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 241000251468 Actinopterygii Species 0.000 abstract 3
- 235000019688 fish Nutrition 0.000 abstract 3
- 241000972773 Aulopiformes Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 235000019515 salmon Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/38011—Tombusviridae
- C12N2770/38022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Farming Of Fish And Shellfish (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291585P | 2021-12-20 | 2021-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001831A1 true CL2024001831A1 (es) | 2024-10-18 |
Family
ID=85221940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001831A CL2024001831A1 (es) | 2021-12-20 | 2024-06-18 | Uso del interferón como adyuvante en vacunas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250057946A1 (https=) |
| EP (1) | EP4452313A1 (https=) |
| JP (1) | JP2025501740A (https=) |
| CN (1) | CN118434443A (https=) |
| AU (1) | AU2022419971A1 (https=) |
| CA (1) | CA3243028A1 (https=) |
| CL (1) | CL2024001831A1 (https=) |
| CO (1) | CO2024007500A2 (https=) |
| CR (1) | CR20240245A (https=) |
| DK (1) | DK202470173A1 (https=) |
| MX (1) | MX2024007696A (https=) |
| WO (1) | WO2023122526A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4208157A1 (en) | 2020-09-04 | 2023-07-12 | Elanco Us Inc. | Palatable formulations |
| DK202370610A1 (en) * | 2022-12-13 | 2024-07-12 | Zoetis Services Llc | Methods of vaccine administration to salmonids |
| CN118956807B (zh) * | 2024-10-17 | 2025-01-24 | 天津赛萌生物技术有限公司 | 一种组蛋白乙酰基转移酶突变体及其在生物大分子制备中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0304634D0 (en) * | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| CA2650730A1 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| WO2014118385A1 (en) * | 2013-02-04 | 2014-08-07 | University of Tromsø | The use of dna sequences encoding an interferon as vaccine adjuvants |
| GB201415789D0 (en) | 2014-09-05 | 2014-10-22 | Touchlight Genetics Ltd | Synthesis of DNA |
| US10456459B2 (en) | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
| CN109844134B (zh) | 2016-08-16 | 2023-05-05 | 塔驰莱特Ip有限公司 | 闭合线性dna的生产 |
| GB201805683D0 (en) | 2018-04-05 | 2018-05-23 | Touchlight Ip Ltd | Reprogramming vectors |
| GB202002068D0 (en) | 2020-02-14 | 2020-04-01 | Touchlight Ip Ltd | DNA synthesis yield improvements |
-
2022
- 2022-12-19 US US18/721,723 patent/US20250057946A1/en active Pending
- 2022-12-19 WO PCT/US2022/081916 patent/WO2023122526A1/en not_active Ceased
- 2022-12-19 AU AU2022419971A patent/AU2022419971A1/en active Pending
- 2022-12-19 EP EP22856944.8A patent/EP4452313A1/en active Pending
- 2022-12-19 JP JP2024537378A patent/JP2025501740A/ja active Pending
- 2022-12-19 CA CA3243028A patent/CA3243028A1/en active Pending
- 2022-12-19 CR CR20240245A patent/CR20240245A/es unknown
- 2022-12-19 CN CN202280084452.5A patent/CN118434443A/zh active Pending
- 2022-12-19 MX MX2024007696A patent/MX2024007696A/es unknown
-
2024
- 2024-06-14 CO CONC2024/0007500A patent/CO2024007500A2/es unknown
- 2024-06-18 CL CL2024001831A patent/CL2024001831A1/es unknown
- 2024-06-19 DK DKPA202470173A patent/DK202470173A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025501740A (ja) | 2025-01-23 |
| DK202470173A1 (en) | 2024-07-12 |
| EP4452313A1 (en) | 2024-10-30 |
| CN118434443A (zh) | 2024-08-02 |
| MX2024007696A (es) | 2024-07-01 |
| CR20240245A (es) | 2024-09-13 |
| CA3243028A1 (en) | 2025-04-07 |
| US20250057946A1 (en) | 2025-02-20 |
| CO2024007500A2 (es) | 2024-07-29 |
| WO2023122526A1 (en) | 2023-06-29 |
| AU2022419971A1 (en) | 2024-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001831A1 (es) | Uso del interferón como adyuvante en vacunas | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| CL2018000320A1 (es) | Coadyuvantes basados en aceite (divisional de solicitud 201600650) | |
| AR112969A1 (es) | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas | |
| ECSP22072586A (es) | VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG | |
| MX2019005617A (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| UY38889A (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15r¿ y su uso | |
| AR105470A1 (es) | Métodos para inducir una respuesta inmune | |
| MX2016012176A (es) | Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. | |
| CO2020006907A2 (es) | Péptidos antimicrobianos y métodos para usarlos | |
| CO2021010786A2 (es) | Toxinas apxia, apxiia y apxiiia inactivadas | |
| CL2019002641A1 (es) | Composiciones y métodos que involucran moléculas probióticas. | |
| CL2015002741A1 (es) | Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos | |
| BR112021017774A2 (pt) | Dose baixa de citocina coadministrada com irgd para tratar câncer | |
| MX2023012390A (es) | Vacunacion con particulas de replicon y adyuvante oleoso. | |
| CO2020013050A2 (es) | Enzimas quinureninasa humanas y sus usos | |
| BR112022020298A2 (pt) | Vacinas, adjuvantes e métodos para gerar uma resposta imune | |
| CL2018002123A1 (es) | Virus de vacuna del síndrome respiratorio y reproductivo porcino | |
| EA202100145A1 (ru) | Применение гуанабенза | |
| AR095939A1 (es) | Vacuna contra garrapatas rhipicephalus | |
| MX2021002444A (es) | Compuestos y metodos para el tratamiento de infecciones fungicas. | |
| CO2024014302A2 (es) | Proteínas cd24 mutantes y usos de las mismas para la profilaxis y el tratamiento del cáncer | |
| CO2021005872A2 (es) | Composiciones y métodos para la estimulación ovárica controlada | |
| CR20180456A (es) | Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas | |
| MX2020003742A (es) | Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos. |